Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Mingfeng Han and Haiming Wei.
Connection Strength

0.735
  1. Reply to Wang et al.: Tocilizumab treatment should be used in a timely manner, at suitable dose, and in suitable patients. Proc Natl Acad Sci U S A. 2020 12 08; 117(49):30898-30899.
    View in: PubMed
    Score: 0.228
  2. Reply to Yang et al.: Tocilizumab treatment in COVID-19 patients needs the assessment of the disease severity and timely intervention. Proc Natl Acad Sci U S A. 2020 12 01; 117(48):30027-30028.
    View in: PubMed
    Score: 0.228
  3. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020 05 19; 117(20):10970-10975.
    View in: PubMed
    Score: 0.220
  4. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Front Med. 2021 Jun; 15(3):486-494.
    View in: PubMed
    Score: 0.058
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.